ArticleCells2019
Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010⁻2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Guideline "Parkinson's disease" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care.Journal of neurology · 2024Guideline
- The Effectiveness of Inpatient Rehabilitation in Parkinson's Disease: A Systematic Review of Recent Studies.Journal of Parkinson's disease · 2024Pooled it
- Long-term effect of the German Parkinson's disease multimodal complex treatment: a clinical trial with randomized allocation.BMC neurology · 2026Trial
- Comprehensive effects of Parkinson's disease multimodal complex treatment (PD-MCT): a two-center prospective trial.Journal of neurology · 2026Trial
- Evaluation of an individualized, tablet-based physiotherapy training programme for patients with Parkinson's disease: the ParkProTrain study, a quasi-randomised controlled trial.BMC neurology · 2022Trial
- Deciphering novel genotypic biomarkers and functional alterations in double strand break repair pathways for Parkinson's disease.Scientific reports · 2026Article
- Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson's disease in Germany and the needs of future development.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Searching for a needle in a haystack-ambulatory research in Parkinson's disease in Germany.Frontiers in aging neuroscience · 2026Article
- Multidisciplinary inpatient care for Parkinson's disease: a single-centre cohort study on improvements in gait, overall motor function, and quality of life.Neurological research and practice · 2025Article
- User groups of inpatient multidisciplinary therapies for Parkinson's disease in Germany: a bicenter prospective observational study.Neurological research and practice · 2025Article
- Opportunities and Limitations of Wrist-Worn Devices for Dyskinesia Detection in Parkinson's Disease.Sensors (Basel, Switzerland) · 2025Article
- Outpatient interface challenges for drug safety in Parkinson's disease patients: a questionnaire based cross-sectional study.Frontiers in neurology · 2025Article
- Medication Adherence in Parkinson's Disease: Longitudinal Changes and the Influence of Depressive Symptoms.Patient preference and adherence · 2025Article
- [Multidisciplinary Complex Treatment of Parkinson's disease : Cornerstone of an individualized treatment].Der Nervenarzt · 2024Review
- Gender gap in deep brain stimulation for Parkinson's disease: preliminary results of a retrospective study.Neurosurgical review · 2024Article
- Clinical and device-based predictors of improved experience of activities of daily living after a multidisciplinary inpatient treatment for people with Parkinson's disease: a cohort study.Therapeutic advances in neurological disorders · 2024Article
- Gait Characteristics Associated with Fear of Falling in Hospitalized People with Parkinson's Disease.Sensors (Basel, Switzerland) · 2023Article
- Impact of the COVID-19 pandemic on perceived access and quality of care in German people with parkinsonism.Frontiers in public health · 2023Article
- Activities of Daily Living Are Improved by Inpatient Multimodal Complex Treatment for PD-a Real-World Cohort Study.Movement disorders clinical practice · 2023Article
- Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is currently the world's fastest-growing neurological disorder. It is characterized by motor and non-motor symptoms which progressively lead to significant clinical impairment, causing a high burden of disease. In addition to pharmacological therapies, various non-pharmacological treatment options are available. A well established and frequently used multiprofessional inpatient treatment concept in Germany is "Parkinson's disease multimodal complex treatment" (PD-MCT) which involves physiotherapists, occupational therapists, speech therapists, and other specializations for the optimization of treatment in PD (ICD G20) and other Parkinsonian syndromes (ICD G21 and G23). In this study we analyze the PD-MCT characteristics of 55,141 PD inpatients who have been integrated into this therapy concept in Germany in the years 2010⁻2016. We demonstrate that PD-MCT is increasingly applied over this time period. Predominately, PD patients with advanced disease stage and motor fluctuations in age groups between 45 and 69 years were hospitalized. In terms of gender, more male than female patients were treated. PD-MCT is provided primarily in specialized hospitals with high patient numbers but a minor part of all therapies is performed in a rather large number of hospitals with each one treating only a few patients. Access to PD-MCT differs widely across regions, leading to significant migration of patients from underserved areas to PD-MCT centers ⁻ a development that should be considered when implementing such therapies in other countries. Furthermore, our data imply that despite the overall increase in PD-MCT treatments during the observational period, the restricted treatment accessibility may not adequately satisfy current patient´s need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.